1. Traumatic Brain Injury (TBI): Secondary neuroinflammation, mitochondrial dysfunction, and axonal injury induced by TBI are key contributors to the early onset of neurodegenerative diseases. Recently, several neuroprotective drugs have been developed in our research. Investigating these drugs offers an opportunity to identify effective strategies to mitigate TBI-related damage and improve patient outcomes.

2. Glioblastoma (GBM): GBM not only exhibits intrinsic oncogenic molecular abnormalities but also actively reprograms its tumor microenvironment (TME) by recruiting and manipulating non-malignant cells to establish a tumor ecosystem. This ecosystem confers resistance to various cancer therapies. While the roles of macrophages, neurons, and microglia in shaping the TME and driving GBM malignancy are well-documented, many other cell types present within the tumor and its periphery remain poorly understood. Disrupting this complex tumor ecosystem represents a promising avenue for innovative cancer cell therapies.